jhu dsip 2022 Second Roadmap on Diversity, Equity, and Inclusion DSIP Program Assistant (Academic Affairs-IDARE)
Description
2018;83(9):10571067.:10.1134/S0006297918090079
PD-1 is being highly investigated to be a therapeutic target against HNSCC progression
2024 Mar;19:ard2023
12 mg remains the highest-efficacy dose, but it carries a meaningfully worse GI burden and a correspondingly higher dropout risk
doi:10.1016/j.clnu.2020.11.035 9Andrs E, Affenberger S, Vinzio S, et al
